BioSpace News Archive

OrthoPediatrics Corp., a Company focused exclusively on advancing the field of pediatric orthopedics, announced that the World Pediatric Project has named OrthoPediatrics its 2020 Corporate Champion of the Year.

On Target Laboratories, Inc., a privately-held biotechnology company developing fluorescent markers to target and illuminate cancer during surgery, today announced that Tommy Lee, MSHS has joined the Company as Vice President, Clinical Operations.

Globally renowned oncology center Institut Curie is leading a study on Ibex’s Galen™ Breast, the first AI-based solution used by pathologists in routine clinical practice for breast cancer detection

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced three amyotrophic lateral sclerosis (ALS) presentations as part of the Motor Neurone Disease Association (MNDA) 31 st International Symposium on ALS/MND, which is being held virtually December 9-11 .

Vault, a performance healthcare technology platform and leader in saliva at-home COVID-19 testing, has announced their latest C-Suite hire, Steve Shi, as Chief Technology Officer.

Enthera Pharmaceuticals announces that it has appointed Kazumi Shiosaki to its Board of Directors, and Lisa Olson to its Scientific Advisory Board.

LivaNova PLC, a market-leading medical technology and innovation company, and Gyrus Capital, an investment firm dedicated to investments in the healthcare and sustainability sectors, announced they have entered into an agreement whereby entities funded and controlled by Gyrus will acquire the LivaNova heart valve business.

As the global economy shifts in the wake of the COVID-19 pandemic, 3M is advancing its operating model, streamlining its business, and focusing on global trends where the company will apply science to life in new ways to drive sustainable growth.

This transaction will be immediately accretive to the Company adding complementary services and insurable revenue to the existing primary care model across 15 States.

A randomized controlled trial demonstrated 70% lower 30-day readmissions and 40% care cost reduction compared with usual hospital care